|Application ||WB, IHC-P, E|
|Calculated MW||71597 Da|
|Antigen Region||144-173 aa|
|Other Names||Wee1-like protein kinase, WEE1hu, Wee1A kinase, WEE1|
|Target/Specificity||This WEE1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 144-173 amino acids from the Central region of human WEE1.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||WEE1 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Acts as a negative regulator of entry into mitosis (G2 to M transition) by protecting the nucleus from cytoplasmically activated cyclin B1-complexed CDK1 before the onset of mitosis by mediating phosphorylation of CDK1 on 'Tyr-15'. Specifically phosphorylates and inactivates cyclin B1-complexed CDK1 reaching a maximum during G2 phase and a minimum as cells enter M phase. Phosphorylation of cyclin B1-CDK1 occurs exclusively on 'Tyr-15' and phosphorylation of monomeric CDK1 does not occur. Its activity increases during S and G2 phases and decreases at M phase when it is hyperphosphorylated. A correlated decrease in protein level occurs at M/G1 phase, probably due to its degradation.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
WEE1 is a nuclear protein, which is a tyrosine kinase belonging to the Ser/Thr family of protein kinases. This protein catalyzes the inhibitory tyrosine phosphorylation of CDC2/cyclin B kinase, and appears to coordinate the transition between DNA replication and mitosis by protecting the nucleus from cytoplasmically activated CDC2 kinase.
Kawasaki, H., et al., Oncogene 22(44):6839-6844 (2003).
Hashimoto, O., et al., Mol. Carcinog. 36(4):171-182 (2003).
Yuan, H., et al., J. Virol. 77(3):2063-2070 (2003).
Masaki, T., et al., Hepatology 37(3):534-543 (2003).
de Noronha, C.M., et al., Science 294(5544):1105-1108 (2001).
If you have any additional inquiries please email technical services at email@example.com.